Abstract
In the event of a “no deal” Brexit some of the UK’s most vulnerable, especially children with rare diseases, may lose access to the best medicine available, say Stuart Elborn, Mark Flear, and Damian Downey.
Original language | English |
---|---|
Type | Blog entry |
Media of output | BMJ Opinion blog |
Publication status | Published - 19 Jul 2019 |
Publication series
Name | BMJ Blogs |
---|